Please login to the form below

Not currently logged in
Email:
Password:

Bayer eyes liver cancer indication for Stivarga

New trial data shows improvement in overall survival in HCC patients
Bayer

Bayer now has phase III results in hand which suggests its Stivarga product is an effective treatment for a common form of liver cancer known as hepatocellular carcinoma (HCC).

The new data come from the RESORCE trial, which showed that Stivarga (regorafenib) was able to improve overall survival in HCC patients whose disease was unsuitable for surgery and had progressed despite earlier treatment with Nexavar (sorafenib), Bayer's already-approved drug for liver cancer.

Stivarga is already labelled for the treatment of colorectal cancer and gastrointestinal stromal tumours (GIST) which has been cited as a growth product for Bayer but saw sales dip in the first-quarter, due mainly to increased competition in the US where it declined 24%.

Overall the product brought in €67m in the first three months of the year, €4m less than a year ago, and a new indication in liver cancer could restore some of its growth momentum.

Meanwhile, Bayer is also looking for a boost from the launch of the drug in Germany - Europe's largest market - in the latter half of this year.

"Effective treatment options are urgently needed for patients with liver cancer,” said Joerg Moeller, Bayer's pharma head, who noted that Stivarga could now sit alongside Nexavar as "the second proven systemic option for the treatment of liver cancer".

Nexavar is still growing strongly, with sales rising almost 10% in the first quarter to reach €213m, and remains the only FDA-approved systemic therapy available for advanced HCC.

However, despite its ability to improve clinical outcomes, the average overall survival for HCC remains between seven and 11 months.

Bayer has indicated that it will submit data from the RESORCE study as the basis for a marketing application for Stivarga in the treatment of inoperable HCC before the end of the year.

HCC is the most common form of liver cancer and represents approximately 70-85% of all cases worldwide. Liver cancer is the sixth most common cancer in the world and the second leading cause of cancer-related deaths globally.

Article by
Phil Taylor

5th May 2016

From: Research, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics